Role of hypoxia in progressive chronic kidney disease and implications for therapy

Current Opinion in Nephrology and Hypertension

Volumn 23, Issue 2, 2014, Pages 161-168

  Shoji, Kumi ^a   Tanaka, Tetsuhiro ^a   Nangaku, Masaomi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Epigenetics; Hypoxia; Hypoxia inducible factor; Proryl hydroxylase

Indexed keywords

ANOXIA; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CELL HYPOXIA; DISEASE PROGRESSION; EPIGENESIS, GENETIC; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; KIDNEY; PROGNOSIS; PROLYL HYDROXYLASES; RENAL INSUFFICIENCY, CHRONIC; SIGNAL TRANSDUCTION;

EID: 84894099179     PISSN: 10624821     EISSN: 14736543     Source Type: Journal    
DOI: 10.1097/01.mnh.0000441049.98664.6c     Document Type: Review

References (72)

1. Fine LG, Orphanides C, Norman JT. Progressive renal disease: the chronic hypoxia hypothesis. Kidney Int Suppl 1998; 65:S74-S78.
2. Mimura I, Nangaku M. The suffocating kidney: tubulointerstitial hypoxia in endstage renal disease. Nat Rev Nephrol 2010; 6:667-678.
3. Wang GL, Semenza GL. General involvement of hypoxia-inducible factor 1 in transcriptional response to hypoxia. Proc Natl Acad Sci U S A 1993; 90:4304-4308.
4. Eltzschig HK, Carmeliet P. Hypoxia and inflammation. N Engl J Med 2011; 364:656-665.
5. Friederich-Persson M, Thorn E, Hansell P, et al. Kidney hypoxia, attributable to increased oxygen consumption, induces nephropathy independently of hyperglycemia and oxidative stress. Hypertension 2013; 62:914-919.
6. Takiyama Y, Harumi T, Watanabe J, et al. Tubular injury in a rat model of type 2 diabetes is prevented by metformin: a possible role of HIF-1alpha expression and oxygen metabolism. Diabetes 2011; 60:981-992.
7. van Gestel YR, Chonchol M, Hoeks SE, et al. Association between chronic obstructive pulmonary disease and chronic kidney disease in vascular surgery patients. Nephrol Dial Transplant 2009; 24:2763-2767.
8. Nicholl DD, Ahmed SB, Loewen AH, et al. Declining kidney function increases the prevalence of sleep apnea and nocturnal hypoxia. Chest 2012; 141:1422-1430.
9. Kanbay A, Buyukoglan H, Ozdogan N, et al. Obstructive sleep apnea syndrome is related to the progression of chronic kidney disease. Int Urol Nephrol 2012; 44:535-539.
10. Iseki K, Tohyama K, Matsumoto T, Nakamura H. High prevalence of chronic kidney disease among patients with sleep related breathing disorder (SRBD). Hypertens Res 2008; 31:249-255.
11. Winkelmayer WC, Liu J, Brookhart MA. Altitude and all-cause mortality in incident dialysis patients. JAMA 2009; 301:508-512.
12. Winkelmayer WC, Hurley MP, Liu J, Brookhart MA. Altitude and the risk of cardiovascular events in incident US dialysis patients. Nephrol Dial Transplant 2012; 27:2411-2417.
13. Pruijm M, Hofmann L, Vogt B, et al. Renal tissue oxygenation in essential hypertension and chronic kidney disease. Int J Hypertens 2013; 2013: 696598.
14. Yin WJ, Liu F, Li XM, et al. Noninvasive evaluation of renal oxygenation in diabetic nephropathy by BOLD-MRI. Eur J Radiol 2012; 81:1426-1431.
15. Inoue T, Kozawa E, Okada H, et al. Noninvasive evaluation of kidney hypoxia and fibrosis using magnetic resonance imaging. J Am Soc Nephrol 2011; 22:1429-1434.
16. Wang ZJ, Kumar R, Banerjee S, Hsu CY. Blood oxygen level-dependent (BOLD) MRI of diabetic nephropathy: preliminary experience. J Magn Reson Imaging 2011; 33:655-660.
17. Iyer NV, Kotch LE, Agani F, et al. Cellular and developmental control of O2 homeostasis by hypoxia-inducible factor 1 alpha. Genes Dev 1998; 12:149-162.
18. Scortegagna M, Ding K, Oktay Y, et al. Multiple organ pathology, metabolic abnormalities and impaired homeostasis of reactive oxygen species in Epas1-/-mice. Nat Genet 2003; 35:331-340.
19. Makino Y, Uenishi R, Okamoto K, et al. Transcriptional up-regulation of inhibitory PAS domain protein gene expression by hypoxia-inducible factor 1 (HIF-1): a negative feedback regulatory circuit in HIF-1-mediated signaling in hypoxic cells. J Biol Chem 2007; 282:14073-14082.
20. Willam C, Maxwell PH, Nichols L, et al. HIF prolyl hydroxylases in the rat; organ distribution and changes in expression following hypoxia and coronary artery ligation. J Mol Cell Cardiol 2006; 41:68-77.
21. Myllyharju J, Koivunen P. Hypoxia-inducible factor prolyl 4-hydroxylases: common and specific roles. Biol Chem 2013; 394:435-448.
22. Rosenberger C, Mandriota S, Jurgensen JS, et al. Expression of hypoxiainducible factor-1alpha and-2alpha in hypoxic and ischemic rat kidneys. J Am Soc Nephrol 2002; 13:1721-1732.
23. Haase VH. Regulation of erythropoiesis by hypoxia-inducible factors. Blood Rev 2013; 27:41-53.
24. Tan Q, Kerestes H, Percy MJ, et al. Erythrocytosis and pulmonary hypertension in a mouse model of human HIF2A gain of function mutation. J Biol Chem 2013; 288:17134-17144.
25. Souma T, Yamazaki S, Moriguchi T, et al. Plasticity of renal erythropoietinproducing cells governs fibrosis. J Am Soc Nephrol 2013; 24:1599-1616
26. Tanaka T, Miyata T, Inagi R, et al. Hypoxia in renal disease with proteinuria and/ or glomerular hypertension. Am J Pathol 2004; 165:1979-1992.
27. Katavetin P, Miyata T, Inagi R, et al. High glucose blunts vascular endothelial growth factor response to hypoxia via the oxidative stress-regulated hypoxiainducible factor/hypoxia-responsible element pathway. J Am Soc Nephrol 2006; 17:1405-1413.
28. Rosenberger C, Khamaisi M, Abassi Z, et al. Adaptation to hypoxia in the diabetic rat kidney. Kidney Int 2008; 73:34-42.
29. Ceradini DJ, Yao D, Grogan RH, et al. Decreasing intracellular superoxide corrects defective ischemia-induced new vessel formation in diabetic mice. J Biol Chem 2008; 283:10930-10938.
30. Chiang CK, Tanaka T, Inagi R, et al. Indoxyl sulfate, a representative uremic toxin, suppresses erythropoietin production in a HIF-dependent manner. Lab Invest 2011; 91:1564-1571.
31. Tanaka T, Yamaguchi J, Higashijima Y, Nangaku M. Indoxyl sulfate signals for rapid mRNA stabilization of Cbp/p300-interacting transactivator with Glu/Asp-rich carboxy-terminal domain 2 (CITED2) and suppresses the expression of hypoxia-inducible genes in experimental CKD and uremia. FASEB J 2013; 27:4059-4075.
32. Schodel J, Klanke B, Weidemann A, et al. HIF-prolyl hydroxylases in the rat kidney: physiologic expression patterns and regulation in acute kidney injury. Am J Pathol 2009; 174:1663-1674.
33. Schodel J, Bohr D, Klanke B, et al. Factor inhibiting HIF limits the expression of hypoxia-inducible genes in podocytes and distal tubular cells. Kidney Int 2010; 78:857-867.
34. Tanaka T, Kojima I, Ohse T, et al. Cobalt promotes angiogenesis via hypoxiainducible factor and protects tubulointerstitium in the remnant kidney model. Lab Invest 2005; 85:1292-1307.
35. Song YR,You SJ, Lee YM,et al.Activation of hypoxia-inducible factor attenuates renal injury in rat remnant kidney. Nephrol Dial Transplant 2010; 25:77-85
36. Tanaka T, Matsumoto M, Inagi R, et al. Induction of protective genes by cobalt ameliorates tubulointerstitial injury in the progressive Thy1 nephritis. Kid Int 2005; 68:2714-2725.
37. Zhang XL, Yan ZW, Sheng WW, et al. Activation of hypoxia-inducible factor-1 ameliorates postischemic renal injury via inducible nitric oxide synthase. Mol Cell Biochem 2011; 358:287-295.
38. Kobayashi H, Gilbert V, Liu Q, et al. Myeloid cell-derived hypoxia-inducible factor attenuates inflammation in unilateral ureteral obstruction-induced kidney injury. J Immunol 2012; 188:5106-5115.
39. Schley G, Klanke B, Schodel J, et al. Hypoxia-inducible transcription factors stabilization in the thick ascending limb protects against ischemic acute kidney injury. J Am Soc Nephrol 2011; 22:2004-2015.
40. Theilig F, Enke AK, Scolari B, et al. Tubular deficiency of von Hippel-Lindau attenuates renal disease progression in anti-GBM glomerulonephritis. Am J Pathol 2011; 179:2177-2188.
41. Hung TW, Liou JH, Yeh KT, et al. Renal expression of hypoxia inducible factor-1alpha in patients with chronic kidney disease: a clinicopathologic study from nephrectomized kidneys. Indian J Med Res 2013; 137:102-110.
42. Kimura K, Iwano M, Higgins DF, et al. Stable expression of HIF-1alpha in tubular epithelial cells promotes interstitial fibrosis. Am J Physiol Renal Physiol 2008; 295:F1023-F1029.
43. Ding M, Cui S, Li C, et al. Loss of the tumor suppressor Vhlh leads to upregulation of Cxcr4 and rapidly progressive glomerulonephritis in mice. Nat Med 2006; 12:1081-1087.
44. Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006; 355:2085-2098.
45. Drueke TB, Locatelli F, Clyne N, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006; 355:2071-2084.
46. Pfeffer MA, Burdmann EA, Chen CY, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009; 361:2019-2032.
47. Szczech LA, Barnhart HX, Inrig JK, et al. Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes. Kidney Int 2008; 74:791-798.
48. Solomon SD, Uno H, Lewis EF, et al. Erythropoietic response and outcomes in kidney disease and type 2 diabetes. N Engl J Med 2010; 363:1146-1155.
49. Peyssonnaux C, Zinkernagel AS, Schuepbach RA, et al. Regulation of iron homeostasis by the hypoxia-inducible transcription factors (HIFs). J Clin Invest 2007; 117:1926-1932.
50. Mole DR, Blancher C, Copley RR, et al. Genome-wide association of hypoxiainducible factor (HIF)-1alpha and HIF-2alpha DNA binding with expression profiling of hypoxia-inducible transcripts. J Biol Chem 2009; 284:16767-16775.
51. Schodel J, Oikonomopoulos S, Ragoussis J, et al. High-resolution genomewide mapping of HIF-binding sites by ChIP-seq. Blood 2011; 117:e207-e217.
52. Xia X, Lemieux ME, Li W, et al. Integrative analysis of HIF binding and transactivation reveals its role in maintaining histone methylation homeostasis. Proc Natl Acad Sci U S A 2009; 106:4260-4265.
53. Shoji K, Murayama T, Mimura I, et al. Sperm-associated antigen 4, a novel hypoxia-inducible factor 1 target, regulates cytokinesis, and its expression correlates with the prognosis of renal cell carcinoma. Am J Pathol 2013; 182:2191-2203.
54. Knaup KX, Monti J, Hackenbeck T, et al. Hypoxia regulates the sperm associated antigen 4 (SPAG4) via HIF, which is expressed in renal clear cell carcinoma and promotes migration and invasion in vitro. Mol Carcinog 2013. [Epub ahead of print]
55. Krieg AJ, Rankin EB, Chan D, et al. Regulation of the histone demethylase JMJD1A by hypoxia-inducible factor 1 alpha enhances hypoxic gene expression and tumor growth. Mol Cell Biol 2010; 30:344-353.
56. Zager RA, Johnson AC. Renal ischemia-reperfusion injury upregulates histone-modifying enzyme systems and alters histone expression at proinflammatory/ profibrotic genes. Am J Physiol Renal Physiol 2009; 296:F1032-F1041.
57. Mimura I, Tanaka T, Nangaku M. Novel therapeutic strategy with hypoxiainducible factors via reversible epigenetic regulation mechanisms in progressive tubulointerstitial fibrosis. Semin Nephrol 2013; 33:375-382.
58. Mimura I, Nangaku M, Kanki Y, et al. Dynamic change of chromatin conformation in response to hypoxia enhances the expression of GLUT3 (SLC2A3) by cooperative interaction of hypoxia-inducible factor 1 and KDM3A. Mol Cell Biol 2012; 32:3018-3032.
59. Lorenzen JM, Haller H, Thum T. MicroRNAs as mediators and therapeutic targets in chronic kidney disease. Nat Rev Nephrol 2011; 7:286-294.
60. Fang Y, Yu X, Liu Y, et al. miR-29c is downregulated in renal interstitial fibrosis in humans and rats and restored by HIF-alpha activation. Am J Physiol Renal Physiol 2013; 304:F1274-1282.
61. Muratsu-Ikeda S, Nangaku M, Ikeda Y, et al. Downregulation of miR-205 modulates cell susceptibility to oxidative and endoplasmic reticulum stresses in renal tubular cells. PloS ONE 2012; 7:e41462.
62. Woroniecki R, Gaikwad AB, Susztak K. Fetal environment epigenetics and pediatric renal disease. Pediatr Nephrol 2011; 26:705-711.
63. Higashijima Y, Tanaka T, Nangaku M. Structure-based drug design for hypoxia-inducible factor prolyl-hydroxylase inhibitors and its therapeutic potential for the treatment of erythropoiesis-stimulating agent-resistant anemia: raising expectations for exploratory clinical trials. Expert Opin Drug Discov 2013; 8:965-976.
64. Kapitsinou PP, Jaffe J, Michael M, et al. Preischemic targeting of HIF prolyl hydroxylation inhibits fibrosis associated with acute kidney injury. Am J Physiol Renal Physiol 2012; 302:F1172-F1179.
65. Wang Z, Schley G, Turkoglu G, et al. The protective effect of prolyl-hydroxylase inhibition against renal ischaemia requires application prior to ischaemia but is superior to EPO treatment. Nephrol Dial Transplant 2012; 27:929-936.
66. Bernhardt WM, Gottmann U, Doyon F, et al. Donor treatment with a PHDinhibitor activating HIFs prevents graft injury and prolongs survival in an allogenic kidney transplant model. Proc Natl Acad Sci U S A 2009; 106:21276-21281.
67. Yu X, Fang Y, Liu H, et al. The balance of beneficial and deleterious effects of hypoxia-inducible factor activation by prolyl hydroxylase inhibitor in rat remnant kidney depends on the timing of administration. Nephrol Dial Transplant 2012; 27:3110-3119.
68. Jamadarkhana P, Chaudhary A, Chhipa L, et al. Treatment with a novel hypoxia-inducible factor hydroxylase inhibitor (TRC160334) ameliorates ischemic acute kidney injury. Am J Nephrol 2012; 36:208-218.
69. Ma D, Lim T, Xu J, et al. Xenon preconditioning protects against renal ischemic-reperfusion injury via HIF-1alpha activation. J Am Soc Nephrol 2009; 20:713-720.
70. Zhao H, Luo X, Zhou Z, et al. Early treatment with xenon protects against the cold ischemia associated with chronic allograft nephropathy in rats. Kidney Int 2013. [Epub ahead of print]
71. Zhao H, Watts HR, Chong M, et al. Xenon treatment protects against cold ischemia associated delayed graft function and prolongs graft survival in rats. Am J Transplant 2013; 13:2006-2018.
72. Jia P, Teng J, Zou J, et al. Intermittent exposure to xenon protects against gentamicin-induced nephrotoxicity. PloS ONE 2013; 8:e64329.